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a b s t r a c t
Human papillomavirus (HPV) has evolved mechanisms that allow it to evade the human immune system.
Studies have shown HPV-mediated suppression of activation of Langerhans cells (LC) is a key mechanism
through which HPV16 evades initial immune surveillance. However, it has not been established whether high-
and low-risk mucosal and cutaneous HPV genotypes share a common mechanism of immune suppression.
Here, we demonstrate that LC exposed to capsids of HPV types 18, 31, 45, 11, (alpha-papillomaviruses) and
HPV5 (beta-papillomavirus) similarly suppress LC activation, including lack of costimulatory molecule
expression, lack of cytokine and chemokine secretion, lack of migration, and deregulated cellular signaling.
In contrast, HPV1 (mu-papillomavirus) induced costimulatory molecule and cytokine upregulation, but LC
migration and cellular signaling was suppressed. These results suggest that alpha and beta HPV genotypes,
and partially a mu genotype, share a conserved mechanism of immune escape that enables these viruses to
remain undetected in the absence of other inﬂammatory events.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human papillomavirus (HPV) infection is causally associated with
the development of benign and malignant lesions, including various
types of cancer (Walboomers et al., 1999). Over 170 genotypes of HPV
have been identiﬁed to date, each with preferential tropism for
particular locations (i.e. mucosal versus cutaneous) and with varying
propensities for causing cancer (i.e. high-risk versus low-risk) (Lizano
et al., 2009). It is estimated that 15% of women with a high-risk HPV
infection are unable to mount an effective immune response (Stanley
et al., 2007), and viral clearance takes on average about one year
(Winer et al., 2011), indicating that HPV possesses mechanisms to
escape immune detection and clearance.
The life cycle of HPV occurs within the epithelium of the skin
and mucosa and is dependent on the differentiation of epithelial
cells, making in vitro studies challenging. As alternatives to native
virions, multiple particle platforms have been developed, such as
virus-like particles (VLPs) and pseudovirions (PsV), which both
generate HPV particles that contain the major capsid protein L1
and minor capsid protein L2 (Kirnbauer et al., 1993; Roden et al.,
1996; Zhou et al., 1991). Due to the location of HPV infection, the
resident antigen presenting cells in the epithelium, Langerhans
cells (LC), are the ﬁrst immune cell to contact HPV and therefore
are thought to be responsible for initiating an effective anti-viral
immune response (Banchereau and Steinman, 1998). Upon recog-
nition of a foreign antigen, LC undergo maturation, which consists
of phenotypic and functional changes including up-regulation of
MHC and co-stimulatory molecules, secretion of cytokines and
chemokines, and migration to regional lymph nodes where T cell
activation takes place (Cunningham et al., 2008). However, we
have previously demonstrated that human LC exposed to the high-
risk genotype HPV16 do not become activated, suggesting a HPV16
immune escape mechanism speciﬁcally targeting LC (Fausch et al.,
2002). We furthermore demonstrated that this HPV16 immune
escape mechanism was dependent on the presence of the minor
capsid protein L2 (Fahey et al., 2009). HPV actively changes the
LC through deregulation of the PI3 kinase (PI3K)-Akt signaling
pathway such that although they present HPV peptides on their
MHC molecules to T cells; this presentation occurs in the absence
of T cell co-stimulatory molecules and essential T cell activating
cytokines (Fausch et al., 2003, 2005a, 2005b). The resulting
immunological phenotype is an LC that can potentially induce T
cell tolerance and/or inhibit subsequent T cell recognition of HPV.
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Whether the LC-speciﬁc immune escape mechanism exhibited
by HPV16 is also utilized by other HPV genotypes, including other
high-risk mucosal genotypes, low-risk mucosal genotypes and
cutaneous genotypes, has been an intriguing question. Because
we had previously shown that the immune escape mechanismwas
dependent on the HPV16 L2 minor capsid protein (Fahey et al.,
2009) and the L2 protein has highly conserved regions across
multiple genotypes (Lowe et al., 2008; Yang et al., 2003), we
hypothesized that other HPV genotypes besides HPV16 would
similarly initiate immune escape by targeting antigen presentation
by LC. To explore this hypothesis, we exposed human monocyte-
derived LC to high-risk mucosal genotypes associated with malig-
nancy (HPV16, HPV18, HPV31 and HPV45), a low-risk mucosal
genotype associated with benign genital condylomas (HPV11) and
cutaneous genotypes associated with skin lesions (HPV5) or hand
and foot warts (HPV1), and subsequently assessed the phenotypic
and functional immunologic characteristics of virus exposed LC.
Results
Phenotypic activation of LC after treatment with high- and low-risk
mucosal HPV genotypes and cutaneous HPV genotypes
HPV particles representative of high-risk mucosal HPV types
(HPV16, HPV18, HPV31, HPV45), a low-risk mucosal HPV type
(HPV11), and cutaneous HPV types (HPV1, HPV5) were generated
by overexpression of the L1 and L2 genes in either insect cells for
virus-like particles (VLP) or in the 293TT human embryonic kidney
cell line for pseudovirions (PsV). To determine the effect of
different HPV genotypes on phenotypic maturation of LC, we
assessed the expression of cell surface activation markers on LC
after exposure to HPV16, HPV18, HPV11, HPV1 VLPs and HPV31,
HPV45, HPV5 PsVs. In line with our previous ﬁndings, LC exposed
to HPV16 expressed comparable levels of MHC class II, the
costimulatory markers CD80 and CD86, and the maturation
marker CD83 compared to untreated LC (Fig. 1). Similarly, LC
exposed to HPV18, HPV31, HPV45, HPV11, and HPV5 also did not
upregulate these cell surface activation markers. In contrast, HPV1
treated LC showed signiﬁcant upregulation of all four surface
molecules (po0.01 compared to untreated LC). LC treated with
the positive control LPS, a potent TLR4 agonist, also upregulated
the cell surface expression of all these activation markers. To rule
out variations in LC activation due to the source of viral particle,
we performed a direct comparison between HPV16 VLP and
HPV16 PsV on LC activation and found no differences in the levels
of LC activation markers (Fig. S1). Titration of HPV1 capsids
resulted in reduced upregulation of surface markers MHC class II
and CD86, although the levels of expression still remained above
that of the untreated cells at the lowest dose tested, indicating that
there is a dose effect for HPV1-induced LC activation (Fig. S2).
Cytokine and chemokine secretion by LC after treatment with
high- and low-risk HPV genotypes and cutaneous HPV genotypes
The cytokine and chemokine proﬁle generated by activated antigen
presenting cells plays an important role in directing the adaptive
immune response. Therefore, to next assess functional activation of LC,
we analyzed the levels of cytokines and chemokines secreted by LC
after exposure to HPV16, HPV18, HPV31, HPV45, HPV11, HPV5 and
HPV1. Secretion of IL-6, TNFα, MIP-1α and RANTES after exposure to
all tested HPV genotypes, except for HPV1, was similar to untreated LC
(Fig. 2). Consistent with the upregulation of activation markers
observed above, LC stimulated with HPV1 demonstrated a signiﬁcant
Fig. 1. High and low risk mucosal HPV genotypes and a cutaneous HPV genotype all suppress phenotypic activation of LC, in contrast to HPV1. Human immature LC were left
untreated, treated with LPS (positive control) or exposed to various HPV genotypes for 48 h at 37 1C. Subsequently, cells were analyzed by ﬂow cytometry for expression of
MHC molecules, costimulatory markers, and maturation markers. Analysis was performed on total population of large cells (475% of total population) which are 495%
CD1aþ (indicative of LC phenotype). Shown are MHC class II, CD80, CD86, and CD83 markers. High-risk mucosal HPV genotypes treated on LC include HPV16, HPV18, HPV31,
and HPV45. HPV11 is the representative low-risk HPV genotype. HPV5 and HPV1 are the representative cutaneous HPV genotypes. Fold change of surface marker expression
was calculated based on mean ﬂuorescence intensity (MFI) normalized against the untreated LC. Data is a representation of mean7SD of LC from 8 healthy donors.
(npo0.05, nnpo0.01).
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increase in the secretion of MIP-1b and RANTES (po0.05), and a
moderate increase in IL-6 and TNFα, indicative of a pro-inﬂammatory
immune response. For the majority of secreted immune mediators
analyzed, LC exposed to the HPV particles maintained baseline
secretion of pro-inﬂammatory cytokines and chemokines analyzed
(Table S1), supporting the view that, in general, LC remain in an
immature state after HPV encounter, particularly with non-cutaneous
genotypes.
Migration of LC in response to exposure with high- and low-risk HPV
genotypes and cutaneous HPV genotype
Once activated, antigen presenting cells migrate to draining
lymph nodes using the cell surface receptor CCR7, which binds to
the lymph node associated chemokine CCL21 (Saeki et al., 1999).
By utilizing a transwell migration assay with CCL21, we assessed
the migratory capacity of LC after exposure to HPV16, HPV18,
HPV31, HPV45, HPV11, HPV5 and HPV1. While exposure to LPS
caused the LC to increase their migration towards CCL21, LC
exposed to all of the HPV types, including HPV1, maintained a
steady state migration similar to untreated LC (Fig. 3), suggesting
that exposure to viral particles does not induce migration of local
LC to lymphocyte-rich areas where immune reactions take place.
Deregulation in the Akt signaling pathway in LC after treatment with
high- and low-risk mucosal HPV genotypes and cutaneous HPV
genotypes
In our previous studies we demonstrated that the mechanism
of HPV16-induced immune escape in LC occurred through the
deregulation of the PI3K–Akt pathway, as shown by a decrease in
phospho-Akt (p-Akt, Ser 473) (Fausch et al., 2005a, 2005b). To
determine if this signaling pathway plays a role in immune escape
of other HPV genotypes, LC were exposed to HPV16, HPV18,
HPV31, HPV45, HPV11, HPV5 and HPV1 and subsequently assayed
for the levels of p-Akt and total Akt. LC exposed to all HPV
genotypes tested demonstrated a decrease in p-Akt compared to
baseline p-Akt levels in untreated LC at 15 min and 30 min post-
exposure (Fig. 4A), indicating they share a common mechanism for
suppressing LC signaling. The relative p-Akt concentration was
Fig. 2. Cytokine and chemokine secretion by LC are similar after treatment with high and low risk HPV genotypes and cutaneous HPV5, in contrast to HPV1. Supernatant
from LC were collected after 48 h of treatment with LC only, LPS, high-risk (HPV16, HPV18 VLPs and HPV31, HPV45 PsV), low-risk (HPV11 VLP) or cutaneous genotypes (HPV5
PsV, HPV1 VLP). Cell supernatants were analyzed for a panel of 12 cytokines and chemokines (IL-1β, IFNα, IL-6, IL-8, IL-10, IL-12 p70, TNFα, IP-10, MCP-1, MIP-1α, MIP-1β,
RANTES) using a Bio-plex suspension bead ELISA (BioRad, Hercules, CA). Shown are four analytes selected from the panel of 12. Data represent the mean(7SEM) analyte
concentration of 4 individual healthy donors tested. (npo0.05, nnpo0.01).
Fig. 3. Migration of LC does not change in response to exposure with high- and
low-risk mucosal and cutaneous HPV genotypes. Human LC were treated with LPS
or HPV genotypes indicated for 48 h and then were analyzed for migration through
a 5 μm transwell insert to medium alone or medium supplemented with 250 ng/
mL CCL21/SLC. After 4 h, cells migrating to the lower chamber containing
chemokine were counted. Visualization of migrating cells by microscopy showed
only large “LC-like” cells moving through the transwell membrane. Shown is the
mean migration index calculated as the number of cells migrating to CCL21 over
spontaneous migration (7SEM) of 6 healthy donors relative to untreated LC. No
signiﬁcant differences are observed between the untreated LC and LC exposed to
different HPV genotypes. (nnpo0.01).
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quantiﬁed and normalized to GAPDH and conﬁrms the decrease in
p-Akt compared to untreated LC (Fig. 4B). The largest decreases in
pAkt were observed after 15 min, whereas by 30 min levels of
pAkt were returning to, but still below baseline. These results
suggest that diverse HPV genotypes are able to cause a down
regulation of signal transduction molecules in LC that normally
control the transcription of immune response genes and cell
survival and point to a potential mechanism for inhibiting the
function of LC in the epidermal tissue during HPV infection.
Discussion
LC, also known as epidermal dendritic cells (DC), only consti-
tute 3–5% of nucleated cells in the epidermis, but are able to form
an expansive cellular network through their extended dendrites
that survey the epidermis for foreign antigens (Romani et al.,
2003). Classically, activated LC are thought to migrate to the lymph
nodes, present antigen and activate antigen-speciﬁc T-cells. How-
ever, recent studies have challenged the importance of LC in the
initiation of skin immunity (Romani et al., 2012). Studies in mice
have identiﬁed a specialized subset of langerinþCD103þ dermal
DC which cross-present antigen to CD8þ T cells when the antigen
is exclusively expressed in keratinocytes (Bedoui et al., 2009;
Henri et al., 2010). Furthermore, long-term effector/memory
CD4þ T cells are induced only when dermal DC are present,
although LC presenting epidermally expressed antigen can still
stimulate CD4þ T cell proliferation (Shklovskaya et al., 2011).
Selective depletion of langerinþ LC in mice results in enhanced
contact hypersensitivity to haptens, suggesting that in the steady-
state, when LC are present, epidermal immune responses are
suppressed (Bobr et al., 2010; Kaplan et al., 2005). Human studies
have shown, however, that LC isolated from human skin can cross-
present antigen, prime naïve CD8þ T cells and preferentially
expand antigen-speciﬁc cytotoxic T lymphocytes (CTLs) (Klechevsky
et al., 2008). Notably, mouse skin and human skin differ quite
substantially both anatomically and immunologically, and it is unclear
whether a human equivalent exists to mouse langerinþCD103þ
dermal DC. Investigation of APC subsets in human vaginal tissue
reveals that vaginal APCs have distinct phenotypes and specialized
functions in directing local immune responses which are different
from other tissues and organs, including skin and gut (Duluc et al.,
2013). LC isolated from human vaginal tissue have been shown to
induce naïve CD8þ T cell proliferation and are able to induce CD8þ T
cells expressing the cytokines IFNγ and TNFα. Overall, it is clear that
human LC can contribute both to immune suppression as well as
immune activation, the outcome being determined by the particular
environment, the presence or absence of inﬂammation and the
presence of pathogenic stimuli.
HPV infections may take many months to years to be cleared
(Ho et al., 1998; Winer et al., 2011), even for non-oncogenic strains
(Giuliano et al., 2002), suggesting that HPVs have acquired the
ability to either remain hidden or suppress the immune system.
Persistence of an HPV infection is the greatest risk factor in the
development of HPV-related malignancies (Schlecht et al., 2001).
Previously, we identiﬁed an HPV16 capsid-driven immune escape
mechanism that suppresses the immunostimulatory function of LC
(Fausch et al., 2003, 2002, 2005a, 2005b. When HPV16, a high risk
mucosal HPV genotype, comes into contact with LC, the result is
that HPV16 actively prevents LC maturation into an activated
antigen presenting cell (APC). The current study indicates that
other HPV genotypes besides HPV16, such as high-risk (HPV18,
HPV31, and HPV45), low-risk (HPV11) and a cutaneous (HPV5)
genotype, also suppress LC activation through a similar mechan-
ism. By inhibiting the maturation of the APC at the site of infection,
these representative HPV genotypes prevent the induction of the
HPV-speciﬁc adaptive immune response required for viral clear-
ance. Human LC have been shown to internalize papillomavirus
capsids from diverse genotypes, including animal papilloma-
viruses (Fausch et al., 2005a; Yan et al., 2004), suggesting that
differential HPV antigen uptake is unlikely to be responsible for
the effects we observed in this study. Notably, APC displaying
peptides in the absence of both costimulation and pro-inﬂammatory
cytokines have the ability to cause T cell anergy (Frauwirth et al.,
Fig. 4. Disruption in the Akt signaling pathway in LC is similar after treatment with high- and low-risk mucosal HPV genotypes and cutaneous HPV genotypes. (A) Cellular
extracts from LC exposed to HPV genotypes for 15 min (top) or 30 min (bottom) at 37 1C were separated by SDS-PAGE, transferred to PVDF and immunoblotted using
antibodies to p-Akt (Ser473), total Akt, and GAPDH. Visualization was performed using the Odyssey Infrared Imaging System. (B) Protein bands were quantiﬁed using the
Odyssey system software, normalized to total Akt and GAPDH expression, and the relative levels of pAkt (mean7SEM) compared to untreated LC are shown from three
individual experiments.
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2000) and generate regulatory T cells (Dhodapkar and Steinman,
2002; Dhodapkar et al., 2001), the latter being increased in HPV-
associated pre-neoplastic lesions and in cervical cancer compared to
healthy tissue (Leong et al., 2010b; Scott et al., 2009; van der Burg
et al., 2007).
To date, 170 genotypes of HPV have been sequenced and are
clustered based on the major L1 capsid, the type of infection
caused (whether mucosal or cutaneous), and their ability to either
induce cancer or benign condylomas (Bernard, 2005; De Villiers,
2013). From the alpha-papillomavirus genus, HPV16 and HPV18 are
most frequently associated with cervical cancer. Importantly, the
four high risk genotypes analyzed in this study – HPV16, HPV18,
HPV31, and HPV45 – are the most prevalent genotypes attributed
to causing greater than 75% of all cervical squamous cell carcinoma
(Smith et al., 2007). Low risk HPV genotypes from the alpha-
papillomavirus group are associated with benign condylomas with
the highest occurrence of genital warts primarily associated with
HPV6 and laryngeal papillomas primarily associated with HPV11.
Cutaneous mu-papillomavirus genotypes such as HPV1 are gener-
ally benign and associated with foot and hand warts. However,
some cutaneous beta-papillomavirus genotypes such as HPV5 and
HPV8 have been associated with epidermodysplasia verruciforms,
a cutaneous neoplastic disease, and can also be associated with
skin cancer in immune compromised individuals (Bernard, 2005).
Although papillomaviruses are distinct enough to be classiﬁed
into different genera and have distinct life-cycle characteristics
and disease associations, one characteristic is fairly consistent –
which is that the majority, if not all, of HPVs tend to persist longer
than the typical transient viral infection. Longitudinal natural
history studies demonstrate that infection with high-risk onco-
genic HPV types persist on average for greater than one year. The
median duration of cervical infection in young women has been
reported to be anywhere from 12–19 months for HPV16 and
HPV31, and 9–15 months for HPV18 and HPV45 (Ho et al., 1998;
Kulmala et al., 2007; Moscicki et al., 2004; Richardson et al., 2003).
Low-risk types such as HPV6 and HPV11 persist on average for six
months (Ho et al., 1998; Richardson et al., 2003). The ability of the
high-risk types (HPV16, 18, 31, 45) to persist longer than a low risk
type (HPV11) despite them being equally capable of inducing LC
dysfunction may be related to other virally mediated mechanisms
contributing to immune escape such as differential modulation of
keratinocyte gene expression, and antiviral and inﬂammatory
cytokines (Kanodia et al., 2007). Similar to the mucosatropic
alpha-papillomaviruses, our data suggest that even cutaneous
HPV genotypes (HPV5 and partially HPV1) can suppress LC
immune function. Clinical observations indicate that cutaneous
warts in healthy individuals generally regress within 3–6 months
with regression being accompanied by dense mononuclear cell
inﬁltrates (Jablonska et al., 1997). However, asymptomatic sub-
clinical infection with cutaneous HPV types is very prevalent and
some studies indicate cutaneous HPVs, such as HPV5, can persist
for months to years (De Koning et al., 2007, 2009; Hazard et al.,
2007). It is interesting to note that LC exposed to HPV1 secreted
increased levels of MIP-1b and RANTES (Fig. 2), two chemokines
that are chemoattractant towards CD4þ T cells, B cells, DC,
monocytes and polymorphonuclear cells. If LC become activated
when HPV1-producing lesions become sufﬁciently large to provide
enough virion stimulation to LC, secretion of these chemokines
may be sufﬁcient to cause mononuclear cell inﬁltration to biolo-
gically promote wart regression.
Related to the potential functional impact on LC suppression by
the HPV capsid proteins of diverse genotypes that we observe,
it has also been shown by Leong et al. that LC numbers and
E-cadherin expression in HPV infected tissue are reduced in
lesions infected with alpha-, gamma- and mu-papillomaviruses,
but not the beta-papillomavirus types indicating that other effects
on LC dysfunction are conserved across diverse HPV genera (Leong
et al., 2010a, 2010b. Moreover, keratinocytes infected with high-
risk HPV16 can block the differentiation of monocytes into LC in a
contact dependent manner (Iijima et al., 2013). These observations,
together with our data, suggest that a consequence of early HPV
infection by a majority of genotypes from diverse genera is to
dampen the immune response via suppression of LC that are
initially present in the epidermis of healthy tissue. Following
infection of keratinocytes, HPV gene expression results in further
host immune suppression by causing a reduction in the LC
adjacent to infected cells, promoting immune evasion and favoring
viral persistence (Kanodia et al., 2007).
In our study, a signiﬁcant amount of capsid was required to
observe partial LC activation by HPV1. When we titrated the HPV1
capsids and decreased the capsid:LC ratio, we did observe that the
upregulation of surface markers was decreased. This observation
suggests that low HPV1 infectious doses would be even less likely
to trigger an antiviral immune reaction, also contributing to
preventing immune recognition despite the fact that some cuta-
neous lesions and warts can become sizable and produce large
amounts of infectious particles. In natural infections, it is not
known how many viral particles are required to alert epidermal LC
to the presence of viral pathogen. However, a signiﬁcant observa-
tion is that some cutaneous HPV infections result in epithelial
tissue which is less corniﬁed, leading to more fragile cell envelopes
that can easily be broken, releasing high concentrations of virions
that can encounter surrounding LC in the infected individual
(Brown and Bryan, 2000). During person to person transmission,
virions can be delivery in concentrated packages by desquamated
corniﬁed cells, releasing a focal amount of virions on a small area
of epithelium (Bryan and Brown, 2001), which would enhance the
likelihood of LC of the uninfected person coming into contact with
a concentrated amount of virions.
Our study reveals that, in general, diverse genotypes (mucosal,
cutaneous, high-risk, and low-risk) tend to interact with human LC
similarly to cause immune suppression. This ﬁnding may allude to
the utilization of similar cell surface receptors on LCs and epithe-
lial cells, though productive infection is not expected to take place
in myeloid-derived immune cells. Early events of papillomavirus
infection are believed to use shared mechanisms based on studies
demonstrating similar infection susceptibility of mucosal and skin
tissues with diverse HPV genotypes (Handisurya et al., 2012).
Additionally, efﬁciency of infection, based on reporter gene trans-
duction, was the same for human and animal papillomavirus
types, suggesting that downstream post-cell entry events deter-
mine papillomavirus species and tissue tropism rather than initial
capsid interactions and virus entry (Handisurya et al., 2012). It is
therefore surprising that in our study certain properties of LC were
different when exposed to the HPV1 cutaneous genotype.
Although LC migration and Akt signaling were not demonstrably
affected, high dose HPV1-exposed LC did become partially acti-
vated through upregulation of surface molecules and secretion of
cytokines involved in adaptive immunity, suggesting that, at least
for HPV1, the host response is more reactive to this papillomavirus
genotype compared to the other genotypes that were used at
the same capsid concentration. Whether these partially activated
LC are able to induce HPV1-speciﬁc T cells in vivo cannot be
determined from our study.
As described earlier, the LC-speciﬁc immune escape mechanism
of HPV16 was shown to be dependent on the presence of the L2
protein, because capsids composed solely of the HPV16 L1 major
capsid protein are capable of activating LC, whereas HPV16 capsids
containing L2 do not (Fahey et al., 2009). Capsids composed solely
of the HPV6b L1 protein have also been shown to activate LC
(Yan et al., 2004). The L2 protein has several conserved regions in
its amino acid sequence across genotypes such as L2(13–31) and
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L2(108–120) which have previously been implicated in cell surface
entry and binding events, respectively (Kawana et al., 2001; Lowe
et al., 2008; Yang et al., 2003). Therefore, suppression of LC across
diverse genotypes may be due to the conserved nature of the L2
protein sequence. Recently, our laboratory has demonstrated that
the HPV16 L2(108–120) region binds to the S100A10 subunit of the
annexin A2 heterotetramer (A2t) on epithelial cells (Woodham
et al., 2012). Further, the interaction between HPV16 L2 and A2t
was shown to contribute to HPV16 internalization and infection,
particularly the L2(108–111) region (Woodham et al., 2012). Impor-
tantly, all of the particles used in this study contained the L2
protein of each genotype (Fig. S3), resulting in use of capsids
identical to physiologically relevant wild-type capsids. Whether
this conserved L2 region of all genotypes mediates the demon-
strated immune escape mechanism, through binding to A2t on LC,
is an active area of research in our group. Supporting this idea, we
have found that HPV16 capsids are taken up by LC and functionally
suppress LC maturation through an interaction with A2t in an
L2-dependent manner (Woodham et al., submitted for publication).
Notably, the L2 proteins from HPV1 and HPV5 contain an extra 34
and 45 amino acids, respectively, compared to HPV16 L2, whereas
the L2 proteins from HPV18, 31 and 45 show more sequence
conservation to HPV16. Interestingly, when key amino acids in the
L2(108–111) region are aligned, the HPV1 L2 sequence is the most
different from HPV16 and the consensus sequence of the region
between the papillomavirus genotypes tested in this study (Fig. 5).
This observation suggests that amino acid divergence in this key
A2t-binding region may be responsible for differential immunolo-
gical outcomes post interaction with LC surface receptors. Addi-
tional studies will be needed to explore whether sequence
differences in the L2 protein between different HPV genotypes
affect their ability to initiate LC immune suppression.
Papillomavirus capsid binding to the cell surface is associated
with epithelial cell signaling, even before the majority of virus is
internalized. One study showed that several high risk HPV geno-
types and bovine papillomavirus induce tyrosine kinase and PI3K
signaling events resulting in downstream signaling to Akt, which
the authors proposed was a result of virus binding to integrins
(Fothergill and McMillan, 2006). In contrast, whereas in epithelial
cells the PI3K pathway is activated, we have previously shown that
HPV16 disconnects PI3K signaling from downstream Akt signaling
and downregulates MAPK signaling in LC (Fausch et al., 2005a,
2005b). The observation that all of the HPV genotypes tested here
appear to suppress Akt signaling in LC extend these ﬁndings to
other HPV genotypes, pointing to a commonmechanism of immune
evasion through deregulated cellular signaling.
While this study evaluated a variety of HPV genotypes from
representative classes, we have not ruled out that genotypes not
tested here may behave differently. HPVs have evolved a variety of
mechanisms for immune escape and likely utilize a combination of
approaches to subvert the immune system and maintain persistent
infections. However, this study suggests a conserved mechanism
of immune escape through targeting LC amongst high-risk, low-
risk and at least one cutaneous HPV genotype, and furthers our
understanding of the interaction between divergent HPV types
and the human immune system.
Materials and methods
Generation of human Langerhans cells
Human Langerhans cells (LC) were derived as described pre-
viously and express phenotypic markers characteristic of skin-
derived LC (Langerinþ , E-cadherinþ , CD11cþ , CD1aþ) (Fig. S1)
(Fausch et al., 2002; Geissmann et al., 1998). These studies were
approved by the University of Southern California Institutional
Review Board and informed consent was obtained from all donors.
HPV pseudovirions and virus-like particles
HPV1, HPV11, HPV16, and HPV18 VLP were produced using a
recombinant baculovirus expression system in Trichoplusia ni (Hi-5)
insect cells as previously described and puriﬁed using sucrose cushion
and cesium chloride density gradient ultracentrifugation (Fausch
et al., 2002; Kirnbauer et al., 1992). HPV5, HPV16, HPV18, HPV31,
and HPV45 pseudovirions were generated in 293TT cells and
puriﬁed by optiprep (iodixinol) density gradient ultracentrifugation
as described previously using the adapted protocol for bulk
replication-incompetent PsV production (Buck and Thompson,
2007). Plasmid constructs (p5sheLL, p16sheLL, p18sheLL, p31sheLL,
p45sheLL) were kindly provided by Dr. John Schiller (National
Cancer Institute). Capsids were subjected to SDS-PAGE and Western
blot analyses to conﬁrm the presence of L1 and L2 proteins (Fig. S3),
while transmission electron microscopy conﬁrmed the presence of
intact particles. Coomassie Blue staining following SDS-PAGE was
performed to determine viral stock purity and standardize the
concentration of L1 content of the VLP and PsV preparations. Capsid
preparations were negative for endotoxin contamination as tested
with an E-toxate (Limulus amebocyte lysate (LAL) assay kit (Sigma-
Aldrich, St. Louis, MO).
LC activation
Immature LC were either left untreated, treated with 5 mg LPS
(Sigma-Aldrich), or 5 mg HPV VLP or PsV/106 cells. LC were incubated
for 1 h at 37 1C, mixed occasionally, then incubated at 37 1C for an
additional 48 h at a cell concentration of 1105 LC/mL. Supernatants
were collected for cytokine analysis and cells were harvested, washed,
stained for surface markers or isotype controls. The following human
antibodies were purchased from BD Biosciences (San Jose, CA): HLA-
DP/DQ/DR-FITC, CD40-PE, CD86-FITC, CD1a-PE, CD197 (CCR7), goat
anti-rat IgG-PE, goat anti-mouse IgG1-FITC, rat IgG2a isotype control,
mouse IgG1-FITC, mouse IgG1-PE, mouse IgG2b-FITC. The following
human antibodies were purchased from Biolegend (San Diego, CA):
HLA-ABC-FITC, CD80-FITC, CD83-PE, CD207-PE (Langerin), CD324-PE
(E-cadherin), Human TruStain FcX (Fc receptor blocking solution).
Samples were analyzed by ﬂow cytometry on a Cytomics FC500 ﬂow
cytometer using CXP software (Beckman Coulter, Indianapolis, IN).
Fig. 5. Alignment and consensus sequence of HPV L2 proteins to HPV16 L2 (aa 108–
111). The sequence of amino acids (108–120) on HPV 16 L2 was shown to bind to
epithelial cells and is conserved between high risk HPV genotypes. L2(108–111) are key
residues mediating binding of L2 to the annexin A2/S100A10 receptor complex. The L2
protein sequences of HPV18, HPV31, HPV45, HPV11, HPV5 and HPV1 were compared
against HPV16. HPV16, HPV18, HPV31, and HPV45 show protein sequence similarity.
HPV1 shows only one conserved amino acid compared to HPV16 in the analyzed region.
Sequences were individually aligned against HPV16 using the NCBI tool COBALT
(COnstraint-Based multiple protein ALignment Tool). The consensus sequence is shown
below the alignment. Asterisks indicate sequence conservation.
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Secreted cytokines and chemokines were analyzed using the
Bio-Plex Suspension Array System (Bio-Rad, Hercules, CA) using a
Milliplex MAP human cytokine/chemokine kit containing detec-
tion reagents for interferon (IFN)α, interleukin (IL)-1β, IL-6, IL-8,
IL-10, IL-12p70, Inducible Protein 10 (IP-10), tumor necrosis factor
(TNF)α, monocyte chemotactic protein (MCP)-1, macrophage
inﬂammatory protein (MIP)-1α, MIP-1β, and RANTES (EMD Milli-
pore, Billerica, MA).
Migration assay
Chemokine directed migration of LC was carried out using 24-
well Transwell plates with 5 μm-pore-size polycarbonate ﬁlters
(Corning Costar, Tewksbury, MA). Media was added to the lower
chamber containing either 250 ng/ml recombinant human CCL21
(R&D Systems, Minneapolis, MN) or medium alone to control for
spontaneous migration. LC untreated or treated as described in the
LC activation assay were added to the upper chamber and
incubated for 4 h at 37 1C. The cells that migrated to the lower
chamber were harvested and counted using a Z1 Beckman Coulter
particle counter. CCL21-dependent migration was calculated as the
ratio of cells that migrated with CCL21 to cells that migrated
spontaneously, termed migration index.
Immunoblotting
LC were treated as described in the activation assay at 37 1C for
15 min. Cellular extracts were prepared using the Mammalian
Protein Extraction Reagent (Thermo Scientiﬁc, Rockford, IL). Equal
concentrations of cell lysates were electrophoresed on 10% NuPage
Novex Bis–Tris gels (Life Technologies) and transferred to PVDF
membranes. Immunoblotting was performed using p-Akt, Akt and
GAPDH antibodies (Cell Signaling Technologies, Danvers, MA) and
species speciﬁc infrared dye labeled secondary antibodies (Thermo
Scientiﬁc). Visualization and quantiﬁcation of bands was per-
formed using the Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE).
Statistical analysis
All statistical analyses were performed using GraphPad Prism
(GraphPad Software Inc., San Diego, CA).
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